Quantcast

Latest Therapies under investigation for multiple sclerosis Stories

2008-09-19 12:00:36

Teva Pharmaceutical Industries has reported new data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis, which demonstrated a significant reduction in the mean number of gadolinium-enhancing lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions...

2008-09-19 12:00:36

Merck Serono, a division of Merck KGaA, has initiated a Phase III trial to evaluate the therapeutic effects of its proprietary oral formulation of cladribine in patients at risk of developing multiple sclerosis. The trial, called Oracle MS will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of multiple sclerosis (MS). Cladribine tablets are currently also being...

2008-09-19 12:00:35

Teva Pharmaceutical Industries has announced new positive data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis, which proves robust efficacy and safety of Copaxone. Findings demonstrated that more than 80% of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years. The majority of the 100 patients in the study experienced either stable or improved disability rates over the duration of the...

2008-09-18 18:00:19

SAN DIEGO, Sept. 18, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that data from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS) was presented today in two poster presentations at the World Congress for Treatment and Research in MS being...

2008-09-18 15:00:12

New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in the mean number of gadolinium-enhancing (GdE) lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In RRMS patients who switched from placebo to laquinimod, 52 percent reduction in the mean number of GdE lesions was observed (p less than 0.0007). The reduction was significant for...

2008-09-17 09:01:00

Merck KGaA has announced that its Merck Serono division has completed patient enrollment in the Reflex trial of Rebif in patients at risk of developing multiple sclerosis. The randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease. A total of 517 patients considered at risk of...

2008-09-16 15:00:11

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today that Dr. Joseph Kovalchin will make a poster presentation titled "Evidence of Specific T-cell Priming from the First-in-Man Single Ascending Dose Study of Peptide Copolymer PI-2301 for the Treatment of Multiple Sclerosis " on Thursday, September 18th from 3:30 - 5:00 p.m. in Exhibit Hall 220C, at the Palais Des Congres de Montreal, Canada at the World Congress on Treatment and...

2008-09-11 09:00:48

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced that top-line data from the company's Phase IIb study of Tovaxin(R) will be presented at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada, on September 19, 2008. Tovaxin, Opexa's lead product candidate, is a novel T-cell vaccine for the...

2008-09-08 18:00:04

WASHINGTON - The government on Friday began posting a list of prescription drugs under investigation for potential safety problems in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a...

2008-09-05 06:00:23

Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'